RBC Capital lowered the firm’s price target on Apellis (APLS) to $21 from $24 and keeps a Sector Perform rating on the shares. The firm has ...

BofA lowered the firm’s price target on Apellis (APLS) to $41 from $44 and keeps a Buy rating on the shares. The firm updated models in ...

Apellis Pharmaceuticals, Inc. has appointed Craig Wheeler, founder and CEO of Headwaters Biotech Advisors, to its Board of Directors, effective immediately. With over 30 years of experience in the ...

WALTHAM, Mass., April 21, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that Craig Wheeler, founder and chief executive officer of Headwaters Biotech ...

WALTHAM, MA - Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), a biotechnology company with a market capitalization of $2.3 billion currently trading near its 52-week low of $17.48, announced the ...

After several weeks and thousands of votes, TV drug ads from Apellis Pharmaceuticals and AstraZeneca found themselves in the final round of the annual #FierceMadness bracket competition. | After ...

Apellis Pharmaceuticals has a 1 year low of $19.76 and a 1 year high of $57.85. The firm has a market cap of $2.51 billion, a price-to-earnings ratio of -9.84 and a beta of 0.85.

We are thrilled to welcome Craig to the Apellis Board of Directors,” said Cedric Francois, M.D., Ph.D., chief executive officer and co-founder, Apellis. “Craig is a seasoned leader, who has ...

WALTHAM, MA - Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), a biotechnology company with a market capitalization of $2.3 billion currently trading near its 52-week low of $17.48, announced the ...